TY - JOUR
T1 - Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson's Disease
T2 - An Update Since 2017
AU - Wamelen, Daniel J Van
AU - Rukavina, Katarina
AU - Podlewska, Aleksandra M
AU - Chaudhuri, K Ray
N1 - Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
PY - 2023
Y1 - 2023
N2 - BACKGROUND: Non-motor symptoms (NMS) are an important and ubiquitous determinant of quality of life in Parkinson's disease (PD). However, robust evidence for their treatment is still a major unmet need.OBJECTIVE: This study aimed to provide an updated review on advances in pharmacological, nonpharmacological, and exercise-based interventions for NMS in PD, covering the period since the publication of the MDS Task Force Recommendations.METHODS: We performed a literature search to identify pharmacological, non-pharmacological, and exercise-based interventions for NMS in PD. As there are recent reviews on the subject, we have only included studies from the 1st of January 2017 to the 1st of December 2021 and limited our search to randomised and non-randomised (including open-label) clinical trials.RESULTS: We discuss new strategies to manage NMS based on data that have become available since 2017, for instance, on the treatment of orthostatic hypotension with droxidopa, several dopaminergic treatment options for insomnia, and a range of non-pharmacological and exercise-based interventions for cognitive and neuropsychiatric symptoms, pain, and insomnia and excessive sleepiness.CONCLUSION: Recent evidence suggests that targeted non-pharmacological treatments, as well as some other NMS management options, may have a significant beneficial effect on the quality of life and need to be considered in the pathways of treatment of PD.
AB - BACKGROUND: Non-motor symptoms (NMS) are an important and ubiquitous determinant of quality of life in Parkinson's disease (PD). However, robust evidence for their treatment is still a major unmet need.OBJECTIVE: This study aimed to provide an updated review on advances in pharmacological, nonpharmacological, and exercise-based interventions for NMS in PD, covering the period since the publication of the MDS Task Force Recommendations.METHODS: We performed a literature search to identify pharmacological, non-pharmacological, and exercise-based interventions for NMS in PD. As there are recent reviews on the subject, we have only included studies from the 1st of January 2017 to the 1st of December 2021 and limited our search to randomised and non-randomised (including open-label) clinical trials.RESULTS: We discuss new strategies to manage NMS based on data that have become available since 2017, for instance, on the treatment of orthostatic hypotension with droxidopa, several dopaminergic treatment options for insomnia, and a range of non-pharmacological and exercise-based interventions for cognitive and neuropsychiatric symptoms, pain, and insomnia and excessive sleepiness.CONCLUSION: Recent evidence suggests that targeted non-pharmacological treatments, as well as some other NMS management options, may have a significant beneficial effect on the quality of life and need to be considered in the pathways of treatment of PD.
KW - Humans
KW - Parkinson Disease/therapy
KW - Sleep Initiation and Maintenance Disorders
KW - Quality of Life
KW - Droxidopa/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85163922216&partnerID=8YFLogxK
U2 - 10.2174/1570159X20666220315163856
DO - 10.2174/1570159X20666220315163856
M3 - Review article
C2 - 35293295
SN - 1875-6190
VL - 21
SP - 1786
EP - 1805
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 8
ER -